ZA200802867B - Fap inhibitors - Google Patents
Fap inhibitorsInfo
- Publication number
- ZA200802867B ZA200802867B ZA200802867A ZA200802867A ZA200802867B ZA 200802867 B ZA200802867 B ZA 200802867B ZA 200802867 A ZA200802867 A ZA 200802867A ZA 200802867 A ZA200802867 A ZA 200802867A ZA 200802867 B ZA200802867 B ZA 200802867B
- Authority
- ZA
- South Africa
- Prior art keywords
- fap inhibitors
- fap
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05108049A EP1760076A1 (en) | 2005-09-02 | 2005-09-02 | FAP Inhibitors |
| EP06849433A EP1919864A2 (en) | 2005-09-02 | 2006-08-31 | Fap inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200802867B true ZA200802867B (en) | 2008-12-31 |
Family
ID=38309561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200802867A ZA200802867B (en) | 2005-09-02 | 2008-04-01 | Fap inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8183280B2 (enExample) |
| EP (2) | EP1760076A1 (enExample) |
| JP (1) | JP2009507011A (enExample) |
| KR (1) | KR20080043383A (enExample) |
| AU (1) | AU2006336854A1 (enExample) |
| CA (1) | CA2627607A1 (enExample) |
| NO (1) | NO20081636L (enExample) |
| RU (1) | RU2008112683A (enExample) |
| WO (1) | WO2007085895A2 (enExample) |
| ZA (1) | ZA200802867B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| CA2696579C (en) | 2007-08-17 | 2017-01-24 | Boehringer Ingelheim International Gmbh | Purine derivatives for use in the treatment of fab-related diseases |
| BRPI0820793A2 (pt) * | 2007-12-10 | 2015-06-16 | Hoffmann La Roche | Seprase como marcador de câncer |
| EP2071337A1 (en) * | 2007-12-10 | 2009-06-17 | F.Hoffmann-La Roche Ag | Seprase as a marker for cancer |
| EP2252582B1 (en) * | 2008-03-05 | 2014-07-23 | National Health Research Institutes | Pyrrolidine derivatives |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| RU2011116223A (ru) * | 2008-09-25 | 2012-10-27 | Моликьюлар Инсайт Фармасьютикалз, Инк. (Us) | Селективные ингибиторы сепразы |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| WO2010083570A1 (en) * | 2009-01-23 | 2010-07-29 | The University Of Sydney | Novel metabolic disease therapy |
| PH12012501037A1 (en) | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US9029501B2 (en) | 2010-11-02 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Method for making macrocycles |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US20140056964A1 (en) * | 2010-12-06 | 2014-02-27 | The University Of British Columbia | Granzyme b inhibitor compositions, methods and uses for promoting wound healing |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP2866842A1 (en) * | 2012-06-29 | 2015-05-06 | GE Healthcare UK Limited | Imaging fibrosis |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| EP2730571A1 (en) * | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| AU2015266654A1 (en) * | 2014-05-30 | 2016-12-01 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| WO2018111989A1 (en) | 2016-12-14 | 2018-06-21 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| ES2988845T3 (es) | 2017-01-09 | 2024-11-21 | Onkosxcel Therapeutics Llc | Procedimientos predictivos y diagnósticos para cáncer de próstata |
| EP3723753A4 (en) * | 2017-12-15 | 2022-01-26 | Praxis Biotech LLC | FIBROBLAST ACTIVATION PROTEIN INHIBITORS |
| CN113811529A (zh) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | 成纤维细胞激活蛋白抑制剂 |
| KR102274077B1 (ko) * | 2019-03-29 | 2021-07-09 | 보령제약 주식회사 | Fap 저해제로서의 피롤리딘 유도체 및 이를 포함하는 약학적 조성물 |
| MX2022005388A (es) | 2019-11-06 | 2022-05-24 | Yuhan Corp | Compuestos de pirrolidina y piperidina. |
| PE20230490A1 (es) * | 2020-03-24 | 2023-03-23 | Tufts College | Agentes para obtencion de imagenes y radiofarmacos dirigidos a la fap, y usos relacionados con los mismos |
| JP2023525082A (ja) | 2020-05-07 | 2023-06-14 | アンスティテュ・クリー | 免疫抑制線維芽細胞集団のバイオマーカーとしてのａｎｔｘｒ１及び免疫療法に対する応答を予測するためのその使用 |
| EP4263535A1 (en) * | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| US20250368637A1 (en) * | 2022-06-21 | 2025-12-04 | Astrazeneca Ab | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide |
| WO2023247488A1 (en) * | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| JP2025525344A (ja) * | 2022-06-21 | 2025-08-05 | アストラゼネカ・アクチエボラーグ | Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド |
| WO2025046043A1 (en) | 2023-08-31 | 2025-03-06 | Stichting Radboud Universitair Medisch Centrum | Endometriosis tracer |
| CN118955616B (zh) * | 2024-05-01 | 2025-09-02 | 杭州景嘉航生物医药科技有限公司 | 一种靶向结合成纤维细胞活化蛋白化合物及应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3017929A (en) * | 1959-01-07 | 1962-01-23 | Beloit Iron Works | Head box with balanced slice body |
| US4873342A (en) * | 1985-04-16 | 1989-10-10 | Suntory Limited | Dipeptide derivative and synthesis and use thereof |
| CA1320734C (en) * | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| JPH0774193B2 (ja) | 1986-07-29 | 1995-08-09 | サントリー株式会社 | ジペプチド誘導体及びその製法並びに用途 |
| EP0280956B1 (en) | 1987-02-23 | 1992-10-21 | Ono Pharmaceutical Co., Ltd. | Thiazolidine derivatives |
| CA2004028C (en) * | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
| US5118811A (en) * | 1989-04-13 | 1992-06-02 | Japan Tobacco Inc. | Amino acid derivatives possessing prolyl endopeptidase-inhibitory activities |
| US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| WO1991018877A1 (en) * | 1990-06-07 | 1991-12-12 | Zeria Pharmaceutical Co., Ltd. | Novel arylalkanoylamine derivative and drug containing the same |
| FR2681864B1 (fr) | 1991-09-27 | 1995-03-31 | Adir | Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO1993023040A1 (en) * | 1992-05-20 | 1993-11-25 | Merck & Co., Inc. | 17-ethers and thioethers of 4-aza-steroids |
| EP0670309A1 (en) * | 1992-11-20 | 1995-09-06 | Japan Tobacco Inc. | Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof |
| JP3810097B2 (ja) * | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−２−イルカルボニル複素環式化合物誘導体 |
| US5756763A (en) | 1993-07-23 | 1998-05-26 | Zaidan Hojin Biseibutsu Kagaku Kenkyukai | Pyrrolidine derivatives |
| JPH07126229A (ja) * | 1993-11-02 | 1995-05-16 | Yoshitomi Pharmaceut Ind Ltd | ジアリールケトン化合物およびその医薬用途 |
| KR960705808A (ko) | 1993-11-09 | 1996-11-08 | 조셉 에프. 디프리마 | 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone) |
| US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| JPH07228529A (ja) | 1994-02-17 | 1995-08-29 | Zeria Pharmaceut Co Ltd | コリンエステラーゼ賦活剤 |
| US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US5863902A (en) | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| EP1134213B1 (en) | 1995-06-06 | 2005-11-02 | Pfizer Inc. | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides |
| IL141471A0 (en) * | 1998-08-21 | 2002-03-10 | Point Therapeutics Inc | Regulation of substrate activity |
| HRP20010738B1 (en) | 1999-03-15 | 2005-02-28 | Axys Pharmaceuticals | N-cyanomethyl amides as protease inhibitors |
| WO2001034594A1 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| AU2001228309A1 (en) | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| AU2001294196B2 (en) | 2000-10-06 | 2005-11-17 | Tanabe Seiyaku Co., Ltd. | Nitrogenous five-membered ring compounds |
| JP2005511475A (ja) | 2001-03-02 | 2005-04-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物 |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| CA2424645A1 (en) * | 2001-06-27 | 2003-01-09 | Probiodrug Ag | New use of dipeptidyl peptidase iv inhibitors |
| FI20011466A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| JP2005504766A (ja) * | 2001-08-16 | 2005-02-17 | プロバイオドラッグ アーゲー | プロリンエンドペプチダーゼ阻害剤の、細胞内シグナルカスケード依存性イノシトール（１，４，５）トリホスフェート濃度調節への使用。 |
| KR20040105853A (ko) * | 2002-04-08 | 2004-12-16 | 토렌트 파마슈티칼스 리미티드 | 티아졸리딘-4-카르보니트릴 및 유사체와디펩티딜-펩티다아제 억제제로서의 용도 |
| EP2204181A3 (en) * | 2002-04-30 | 2010-09-22 | Trustees Of Tufts College | Protease inhibitors |
| JP2006506442A (ja) | 2002-07-09 | 2006-02-23 | ポイント セラピューティクス， インコーポレイテッド | ボロプロリン化合物併用療法 |
| MXPA05001536A (es) * | 2002-08-30 | 2005-04-19 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| KR20080030079A (ko) * | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
-
2005
- 2005-09-02 EP EP05108049A patent/EP1760076A1/en not_active Withdrawn
-
2006
- 2006-08-31 KR KR1020087007975A patent/KR20080043383A/ko not_active Withdrawn
- 2006-08-31 CA CA002627607A patent/CA2627607A1/en not_active Abandoned
- 2006-08-31 RU RU2008112683/04A patent/RU2008112683A/ru not_active Application Discontinuation
- 2006-08-31 WO PCT/IB2006/003512 patent/WO2007085895A2/en not_active Ceased
- 2006-08-31 US US11/991,286 patent/US8183280B2/en not_active Expired - Fee Related
- 2006-08-31 AU AU2006336854A patent/AU2006336854A1/en not_active Abandoned
- 2006-08-31 EP EP06849433A patent/EP1919864A2/en not_active Withdrawn
- 2006-08-31 JP JP2008528601A patent/JP2009507011A/ja active Pending
-
2008
- 2008-04-01 ZA ZA200802867A patent/ZA200802867B/xx unknown
- 2008-04-02 NO NO20081636A patent/NO20081636L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008112683A (ru) | 2009-10-20 |
| CA2627607A1 (en) | 2007-08-02 |
| NO20081636L (no) | 2008-05-29 |
| US8183280B2 (en) | 2012-05-22 |
| WO2007085895A3 (en) | 2008-04-17 |
| KR20080043383A (ko) | 2008-05-16 |
| EP1760076A1 (en) | 2007-03-07 |
| US20100081701A1 (en) | 2010-04-01 |
| AU2006336854A1 (en) | 2007-08-02 |
| WO2007085895A2 (en) | 2007-08-02 |
| JP2009507011A (ja) | 2009-02-19 |
| EP1919864A2 (en) | 2008-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200802867B (en) | Fap inhibitors | |
| ZA200707650B (en) | Azolylacylguanidines as ß-secretase inhibitors | |
| IL179398A0 (en) | Dpp-ib inhibitors | |
| EP1906945A4 (en) | HCV INHIBITORS | |
| SI1934236T1 (sl) | Heterobifunkcionalni inhibitorji pan-selektina | |
| ZA200702394B (en) | Indozolone derivatives as 11b-HSD1 inhibitors | |
| ZA200608221B (en) | Thiadlazolidinones as GSK-3 Inhibitors | |
| ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
| IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
| ZA200700181B (en) | Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors | |
| IL189048A0 (en) | Gsk-3 inhibitors | |
| HRP20130810T1 (en) | Sulphonylpyrroles as hdac inhibitors | |
| ZA200805386B (en) | MIF inhibitors | |
| GB0802120D0 (en) | Ramp | |
| GB0421355D0 (en) | Inhibitors | |
| GB0515327D0 (en) | Comt inhibitors | |
| GB0421356D0 (en) | Inhibitors | |
| GB0516967D0 (en) | Inhibitors | |
| ZA200711069B (en) | HCV inhibitors | |
| GB0503644D0 (en) | Catstep I | |
| GB0506443D0 (en) | Novel inhibitors | |
| GB0408300D0 (en) | Novel inhibitors | |
| HU0400020V0 (en) | Case for cigarette-packet | |
| ZAA200501265S (en) | Pilley block | |
| GB0504551D0 (en) | Thing |